| Autor: |
Savulescu F; Department of Medical-Surgical Specialities, 'Titu Maiorescu' University of Bucharest, 040441 Bucharest, Romania.; Central Military University Emergency Hospital 'Dr. Carol Davila', 010242 Bucharest, Romania., Cirlan C; Department of Medical-Surgical Specialities, 'Titu Maiorescu' University of Bucharest, 040441 Bucharest, Romania.; Central Military University Emergency Hospital 'Dr. Carol Davila', 010242 Bucharest, Romania., Iordache-Petrescu MI; Central Military University Emergency Hospital 'Dr. Carol Davila', 010242 Bucharest, Romania., Iordache M; Central Military University Emergency Hospital 'Dr. Carol Davila', 010242 Bucharest, Romania., Petrescu AB; Central Military University Emergency Hospital 'Dr. Carol Davila', 010242 Bucharest, Romania., Blajut C; Central Military University Emergency Hospital 'Dr. Carol Davila', 010242 Bucharest, Romania. |
| Abstrakt: |
COVID-19 has significantly affected public health, social life, and economies worldwide. The only effective way to combat the pandemic is through vaccines. Although the vaccines have been in use for some time, safety concerns have still been raised. The most typical adverse effects of receiving a COVID-19 vaccine are localized reactions near the injection site, followed by general physical symptoms such as headaches, fatigue, muscle pain, and fever. Additionally, some people may experience VITT (vaccine-induced immune thrombotic thrombocytopenia), a rare side effect after vaccination. We present the case of a 60-year-old female patient that developed VITT-like symptoms with spleno-portal thrombosis and intestinal ischemia two weeks after the administration of the Ad26.COV2-S vaccine. Surgical treatment consisted of extensive bowel resection with end jejunostomy and feeding ileostomy. Two weeks after the first operation, a duodenal-ileal anastomosis was performed. The patient was discharged five weeks after the onset of the symptoms. Although some rare adverse effects are associated with the SARS-CoV-2 vaccines, the risk of hospitalization from these harmful effects is lower than the risk of hospitalization from COVID-19. Therefore, recognizing VITT is significant for ensuring the early treatment of clots and proper follow-up. |
